Q-omics provides the consensus-scored MTCYBP3 profile across patient tissues and cancer cell-line models. MTCYBP3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MTCYBP3 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, MTCYBP3 RNA expression shows 6,483 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, LUSC, and STAD as cancer lineages where MTCYBP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCYBP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCYBP3 survival associations across molecular data types. MTCYBP3 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCYBP3 RNA expression–survival associations across cancer types. High MTCYBP3 expression shows unfavorable associations in KICH, UVM, SKCM, MESO and READ, but favorable associations in LIHC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for MTCYBP3 RNA expression.
This table summarizes MTCYBP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MTCYBP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCYBP3 shows lower tumor expression in THCA and higher tumor expression in LUSC and KICH. The LUSC box plot shows higher MTCYBP3 RNA expression in tumor versus normal tissue (log2 FC = +0.047, t-test p = .038).
This table shows molecular features associated with MTCYBP3 in patient tissues and cancer cell lines. In patient samples, MTCYBP3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
